港股異動 | 中國有贊(8083.HK)漲逾8% 有贊科技正式遞交上市申請
格隆匯8月30日丨中國有贊(8083.HK)漲逾8%,報0.79港元,總市值136億港元。

中國有贊於8月30日發出聯合公吿更新有贊科技已就通過發售新股份的方式而非以介紹的方式上市向聯交所提交申請,最大發行股份數不超過現有股數的5%,發行價格將在詢價後釐定。除此外沒有對建議作出重大變動。根據建議,每股中國有讚的計劃股份收取現金0.1352港元和0.0507765股有贊科技股份。
港交所在2018年2月推行上市改革,提高GEM上市要求,並取消了轉往主板上市的簡易轉板機制。中國有贊為了在主板上市,早前建議私有化及將中國有贊所持有的有贊科技股份進行實物分派。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.